Evidence mapPaperPMID 34538573Full record

ReviewBest practice & research. Clinical rheumatology2021

A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc.

Lesley Ann Saketkoo, Tracy Frech, Cecília Varjú, Robyn Domsic, Jessica Farrell, Jessica K Gordon, Carina Mihai, Nora Sandorfi, Lee Shapiro, Janet Poole and 43 more

Open access · bronzeAbstract readReview
In one paragraph

Review in Best practice & research. Clinical rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Copeptin as a Biomarker of Microcirculation Alterations in Systemic Sclerosis.Clinical, cosmetic and investigational dermatology · 2023
    Article
  11. Article
  12. Observational
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

53 authors at 20 institutions in 15 countries.

Lesley Ann SaketkooNew Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, USA; Tulane University School of Medicine, New Orleans, USA; Louisiana State University School of Medicine, Section of Pulmonary Medicine, New Orleans, USA; University Medical Center - Comprehensive Pulmonary Hypertension Center and Interstitial Lung Disease Clinic Programs, New Orleans, USA. Electronic address: lsaketk@tulane.edu.
Tracy FrechVanderbilt University Medical Center, Nashville, TN, USA.
Cecília VarjúDepartment of Rheumatology and Immunology, Medical School, University of Pécs, Pécs, Hungary.
Robyn DomsicUniversity of Pittsburgh, Pittsburgh, PA, USA.
Jessica FarrellAlbany College of Pharmacy and Health Sciences, Albany, NY, USA; Steffens Scleroderma Foundation, Albany, NY, USA.
Jessica K GordonDepartment of Rheumatology at Hospital for Special Surgery, New York, NY, USA.
Carina MihaiDepartment of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; Department of Internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Nora SandorfiPerelman School of Medicine, Philadelphia, PA, USA.
Lee ShapiroSteffens Scleroderma Foundation, Albany, NY, USA; Division of Rheumatology, Albany Medical Center, Albany, NY, USA.
Janet PooleOccupational Therapy Graduate Program, University of New Mexico, Albuquerque, NM, USA.
Elizabeth R VolkmannUniversity of California, David Geffen School of Medicine, UCLA Scleroderma Program and UCLA CTD-ILD Program, Division of Rheumatology, Department of Medicine, Los Angeles, CA, USA.
Monika LammiOchsner Medical Center, New Orleans, LA, USA.
Kendra McAnallyNorton Thoracic Institute, St. Joseph's Hospital and Medical Centre, Phoenix, AZ, USA.
Helene AlexandersonFunction Allied Health Professionals, Medical Unit Occupational Therapy and Physiotherapy, Karolinska University Hospital, Stockholm, Sweden; Department of Medicin, Solna, Karolinska Institutet, Stockholm, Sweden.
Henrik PetterssonFunction Allied Health Professionals, Medical Unit Occupational Therapy and Physiotherapy, Karolinska University Hospital, Stockholm, Sweden; Department of Medicin, Solna, Karolinska Institutet, Stockholm, Sweden.
Faye HantDivision of Rheumatology, Medical University of South Caroline, SC, USA.
Masataka KuwanaDepartment of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan.
Ami A ShahDepartment of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Vanessa SmithDepartment of Internal Medicine, Ghent University, and Department of Rheumatology, Ghent University Hospital, Ghent, Belgium.
Vivien HsuRutgers- RWJ Scleroderma Program, New Brunswick, NJ, USA.
Otylia Kowal-BieleckaDepartment of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland.
Shervin AssassiRheumatology, University of Texas Health Science Center at Houston, Houston, TX, USA.
Maurizio CutoloResearch Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genova, Italy.
Cristiane KayserEscola Paulista de Medicina, Federal University of São Paulo (UNIFESP) São Paulo, SP, Brazil.
Victoria K ShanmugamDepartment of Rheumatology, George Washington University, School of Medicine and Health Sciences, Washington, DC, USA.
Madelon C VonkDepartment of the rheumatic diseases, Radboud University Medical Center, Nijmegen, the Netherlands.
Kim FligelstonePatient Research Partner, Scleroderma & Raynaud Society UK (SRUK), London, UK; Royal Free Hospital, London, UK.
Nancy BaldwinPatient Research Partner, Scleroderma Foundation, Chicago, IL, USA.
Kerri ConnollyScleroderma Foundation, Danvers, MA, USA.
Anneliese RonnowFederation of European Scleroderma Associations, Copenhagen, Denmark; Federation of European Scleroderma Associations, Budapest, Hungary; Federation of European Scleroderma Associations, London, UK.
Beata TothFederation of European Scleroderma Associations, Copenhagen, Denmark; Federation of European Scleroderma Associations, Budapest, Hungary; Federation of European Scleroderma Associations, London, UK.
Maureen SuaveScleroderma Canada, Canada.
Sue FarringtonPatient Research Partner, Scleroderma & Raynaud Society UK (SRUK), London, UK; Federation of European Scleroderma Associations, Copenhagen, Denmark; Federation of European Scleroderma Associations, Budapest, Hungary; Federation of European Scleroderma Associations, London, UK.
Elana J BernsteinColumbia University/New York-Presbyterian Scleroderma Program, Division of Rheumatology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA.
Leslie J CroffordVanderbilt University Medical Center, Nashville, TN, USA.
László CzirjákDepartment of Rheumatology and Immunology, Medical School, University of Pécs, Pécs, Hungary.
Kelly JensenTulane University School of Medicine, New Orleans, USA; Oregon Health and Science University, Portland, OR, USA.
Monique HinchclifYale School of Medicine, Department of Internal Medicine, Section of Rheumatology, Allergy & Immunology, USA.
Marie HudsonDivision of heumatology and Department of Medicine, Jewish General Hospital and McGill University, Montreal, QC, Canada.
Matthew R LammiNew Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, USA; Louisiana State University School of Medicine, Section of Pulmonary Medicine, New Orleans, USA; University Medical Center - Comprehensive Pulmonary Hypertension Center and Interstitial Lung Disease Clinic Programs, New Orleans, USA.
Jennifer MansourTulane University School of Medicine, New Orleans, USA.
Nadia D MorganDepartment of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Fabian MendozaRheumatology Division, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA.
Mandana NikpourJefferson Institute of Molecular Medicine and Scleroderma Center, Thomas Jefferson University, Philadelphia, PA, USA.
John PaulingUniversity of Melbourne, Melbourne at St. Vincent's Hospital Melbourne, Victoria, Australia.
Gabriela RiemekastenRoyal National Hospital for Rheumatic Diseases, Bath, UK; University of Lübeck, University Clinic of Schleswig-Holstein, Dept Rheumatology and Clinical Immunology, Lübeck, Germany.
Anne-Marie RussellUniversity of Exeter, College of Medicine and Health, Exeter, UK.
Mary Beth ScholandUniversity of Utah, Division of Pulmonary Medicine, Pulmonary Fibrosis Center, Salt Lake City, UT, USA.
Elise SeigartDepartment of Rheumatology and Clinical Immunology Charité - Universitätsmedizin Berlin and Berlin Institute of Health, Berlin, Germany.
Tatiana Sofia Rodriguez-ReynaInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Laura HummersDepartment of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Ulrich WalkerDept. of Rheumatology, Basel University Hospital, Basel, Switzerland.
Virginia SteenDivision of Rheumatology, Department of Medicine, Georgetown University, Washington, DC, USA.
University Medical Center New Orleans · USThomas Jefferson University · USUniversity of Pecs · HUBerlin Institute of Health at Charité - Universitätsmedizin Berlin · DEGeorge Washington University · USJohns Hopkins University · USOchsner Medical Center · USOspedale Policlinico San Martino · ITVanderbilt University Medical Center · USAlbany College of Pharmacy and Health Sciences · USAlbany Medical Center Hospital · USColumbia University · USGeorgetown University · USGhent University Hospital · BEHospital for Special Surgery · USInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXKarolinska Institutet · SEKarolinska University Hospital · SELouisiana State University · USMcGill University · CA

Funding

Mediators of Fibrosis in Scleroderma Skin and LungR01AR050840 · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2003 to 2005
$1.1M
Pathogenic Wnt-beta catenin target genes in macrophages and fibrosisR01AR073270 · NIAMS · YALE UNIVERSITY · PI MONIQUE Evangeline HINCHCLIFF · 2022 to 2022
$651k
Pulmonary Focused Foundations in Innovation and Scholarship (PuFFInS)T32HL144470 · MEDICAL UNIVERSITY OF SOUTH CAROLINA · 2025 to 2025
$261k
NHLBI NIH HHS K23 HL150237NHLBI NIH HHS L30 HL129466NHLBI NIH HHS T32 HL144470NIAMS NIH HHS R01 AR050840NIAMS NIH HHS R01 AR073270
6 · The paper itself

Abstract

Systemic sclerosis (SSc), the most lethal of rheumatologic conditions, is the cause of death in >50% of SSc cases, led by pulmonary fibrosis followed by pulmonary hypertension and then scleroderma renal crisis (SRC). Multiple other preventable and treatable SSc-related vascular, cardiac, gastrointestinal, nutritional and musculoskeletal complications can lead to disability and death. Vascular injury with subsequent inflammation transforming to irreversible fibrosis and permanent damage characterizes SSc. Organ involvement is often present early in the disease course of SSc, but requires careful history-taking and vigilance in screening to detect. Inflammation is potentially reversible provided that treatment intensity quells inflammation and other immune mechanisms. In any SSc phenotype, opportunities for early treatment are prone to be under-utilized, especially in slowly progressive phenotypes that, in contrast to severe progressive ILD, indolently accrue irreversible organ damage resulting in later-stage life-limiting complications such as pulmonary hypertension, cardiac involvement, and malnutrition. A single SSc patient visit often requires much more physician and staff time, organization, vigilance, and direct management for multiple organ systems compared to other rheumatic or pulmonary diseases. Efficiency and efficacy of comprehensive SSc care enlists trending of symptoms and bio-data. Financial sustainability of SSc care benefits from understanding insurance reimbursement and health system allocation policies for complex patients. Sharing care between recognised SSc centers and local cardiology/pulmonary/rheumatology/gastroenterology colleagues may prevent complications and poor outcomes, while providing support to local specialists. As scleroderma specialists, we offer a practical framework with tools to facilitate an optimal, comprehensive and sustainable approach to SSc care. Improved health outcomes in SSc relies upon recogntion, management and, to the extent possible, prevention of SSc and treatment-related complications.

Indexed as

Hypertension, PulmonaryLung Diseases, InterstitialScleroderma, SystemicHumansLungPatient CareDisabilityInterstitial lung diseasePulmonary fibrosisPulmonary hypertensionQuality of lifeRenal crisisSclerodermaSymptom burdenSystemic sclerosis

Identifiers

PMID34538573
PMCPMC8670736
OpenAlexW3200613103

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.